

Figure 6A is a profile of the results of combined treatment with 5-fluorouracil and anti-VLA-4 murine monoclonal antibody HP1/2. Symbols are as described for Figure 3.

Figure 6B is a profile of the results of 5-fluorouracil treatment alone.

Figure 7A is the nucleotide sequences of the  $V_H$ -encoding regions having CDR-  
(SEQ ID NO:3)  
encoding sequences from murine HP1/2 transplanted therein.

Figure 7B is the nucleotide sequence of the transplanted  $V_K$  sequence.  
(SEQ ID NO:4)

Figure 8A is a nucleotide sequences encoding the variable regions of the heavy  
and light chains of the humanized anti-VLA-4 antibody hHP1/2 encoding the  $V_H$  region.  
(SEQ ID NO:5)

Figure 8B is the nucleotide sequence encoding the  $V_K$  region.  
(SEQ ID NO:6)

Figure 9 is a profile of the results of treatment with humanized anti-VLA-4 antibody hHP1/2. Symbols are as described for Figure 3.

Figure 10 is a profile of the results of treatment with murine Fab fragments of anti-VLA-4 antibody HP1/2. Symbols are as described for Figure 3.--

For the Examiner's convenience, applicants are submitting herewith substitute pages with these changes indicated.

IN THE CLAIMS:

Please amend the claims as follows:

1. (Amended) A method of peripheralizing CD34+ cells in vivo comprising the steps of administering [a blocking agent of] an anti-VLA-4 antibody or an anti-VCAM-1 antibody which blocks the binding of VLA-4 antigen on the surface of the CD34+ cells to VCAM or fibronectin.
2. (Amended) The method according to claim 1, wherein the [blocking agent is selected from the group consisting of] anti-VLA-4 or anti-VCAM-1 antibody [which may optionally be] <sup>a mouse</sup> ~~is~~ human, chimeric, single chain, or humanized or Fab, Fab', F(ab')<sub>2</sub> or F(v) fragments thereof, ~~fibronectin, fibronectin having an alternatively spliced non-type III connecting segment, fibronectin peptides containing the amino acid sequence EILDV or a similar conservatively substituted amino acid sequence that blocks VLA-4 mediated~~

4  
B  
B  
adhesion, soluble VCAM-1, bifunctional VCAM-1/Ig fusion proteins and VCAM-1 peptides.

4. (Amended) The method of claim 1, further comprising the step of administering a

B B1) cytokine or 5-fluorouracil as a stimulating agent of CD34+ cell proliferation in vivo.

5. (Amended) The method according to claim 2, further comprising the step of administering a cytokine or 5-fluorouracil as a stimulating agent of CD34+ cell proliferation in vivo. B2)

6. (Amended) The method according to claim 3, further comprising the step of administering a cytokine or 5-fluorouracil as a stimulating agent of hematopoietic stem cell proliferation in vivo. B3)

7. (Amended) The method according to claim 4, wherein the stimulation is mediated <sup>by</sup> [5-fluorouracil or] a cytokine selected from the group consisting of granulocyte colony-stimulating factor (G-CSF), stem cell factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), totipotent stem cell factor (T-SCF), stem cell proliferation factor (SCPF), interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-6 (IL-6) and interleukin-11 (IL-11). B

8. (Amended) The method according to claim 5, wherein the stimulation is mediated by [5-fluorouracil or] a cytokine selected from the group consisting of G-CSF, stem cell factor, GM-CSF, M-CSF, T-SCF, SCPF, IL-1, IL-2, IL-3, IL-4, IL-6 and IL-11. B4)

9. (Amended) The method according to claim 6, wherein the stimulation is mediated by [5-fluorouracil or] a cytokine selected from the group consisting of G-CSF, stem cell factor, GM-CSF, M-CSF, T-SCF, SCPF, IL-1, IL-2, IL-3, IL-4, IL-6 and IL-11. B5)

13. (Amended) The method according to claim 10, wherein the [cytokine] G-CSF is administered before administering the [blocking agent of a] anti-VLA-4 antibody or anti-VCAM-1 antibody [VLA-4 antigen on the surface of the CD34+ cells].